Epstein–Barr virus nuclear antigen 1 peptide–major histocompatibility complex (EBNA1 pMHC)

The Epstein–Barr virus nuclear antigen 1 (EBNA1) peptide–major histocompatibility complex (pMHC) is a critical immunological target found on the surface of B cells infected with EBV and in various EBV-associated malignancies (Young & Rickinson, 2004). EBNA1 is a multifunctional viral protein essential for the replication, segregation, and maintenance of the EBV episome during latent infection (Sivachandran et al., 2012). While EBNA1 itself is an intracellular protein, processed peptides such as the HLA-A*02:01-restricted VLPDVLHLL epitope are presented by MHC Class I molecules on the cell surface (He et al., 2021). This presentation allows the immune system, or engineered therapeutic agents, to identify and eliminate cells harboring the virus. In the context of oncology, EBNA1 is uniquely expressed across all patterns of EBV latency, making the EBNA1 pMHC a near-universal marker for EBV-positive tumors, including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorders (Long et al., 2011). Therapeutic interventions targeting this complex primarily involve T-cell receptor (TCR)-like antibodies and chimeric antigen receptor (CAR) T-cells designed to recognize the specific peptide-HLA configuration (Eureka Therapeutics, 2023). These therapies aim to provide a highly specific strike against malignant B cells while minimizing damage to healthy, non-infected tissues. However, challenges such as HLA downregulation by tumor cells and potential cross-reactivity with similar human self-peptides remain significant considerations in drug development (Tang et al., 2014).

Other names

EBNA1-HLA complexEBNA1 peptide-HLA-A*02:01EBV EBNA1 pMHCEBNA1-MHC Class I complexEpstein-Barr virus nuclear antigen 1 peptide-MHC

Therapeutic agents such as TCR-like antibodies or CAR-T cells specifically bind to the EBNA1-derived peptide (e.g., VLPDVLHLL) presented by MHC Class I molecules on the surface of infected B cells, triggering targeted cytotoxicity and immune-mediated destruction of the malignant or infected cell.